Data / Drug companies / Bpi Labs LLC
Bpi Labs LLC: 37 products in the FDA NDC directory, labeler code 54288
Bpi Labs LLC (labeler code 54288) lists 37 products in the FDA National Drug Code Directory, covering 21 finished drugs by generic name. By type: 37 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 14, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 54288
- Products in commercial distribution
- 37
- Packages
- 45
- Finished drugs by generic name
- 21
- Prescription products
- 37
- Over the counter products
- 0
- Controlled substance products
- Schedule III 2, Schedule IV 3
- Flagged as original packager
- 34 of 34 products that carry the flag
- Started marketing in the last 12 months
- 4
- Earliest marketing start
- August 8, 2014
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 21 | 56.8% |
| New drug applications (NDA) | 8 | 21.6% |
| Other unapproved drugs | 8 | 21.6% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 37 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 12 | 32.4% |
| Injection | 11 | 29.7% |
| Solution | 4 | 10.8% |
| Injection, solution, concentrate | 3 | 8.1% |
| Capsule | 3 | 8.1% |
| Injection, powder, lyophilized, for solution | 1 | 2.7% |
| Kit | 1 | 2.7% |
| Powder, for solution | 1 | 2.7% |
| Solution/ drops | 1 | 2.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Testosterone cypionate | 54288-156 | Injection, solution | Generic drugs (ANDA) | September 14, 2026 |
| Testosterone cypionate | 54288-150 | Injection, solution | Generic drugs (ANDA) | September 14, 2026 |
| Trimethobenzamide Hydrochloride | 54288-158 | Injection | Generic drugs (ANDA) | July 1, 2026 |
| Fluorescein | 54288-179 | Injection, solution | Generic drugs (ANDA) | May 20, 2026 |
| Zoledronic Acid | 54288-183 | Injection, solution, concentrate | Generic drugs (ANDA) | June 5, 2025 |
| Dehydrated Alcohol | 54288-144 | Injection, solution | New drug applications (NDA) | April 1, 2025 |
| Epinephrine | 54288-152 | Injection | New drug applications (NDA) | March 21, 2024 |
| Epinephrine | 54288-119 | Injection | New drug applications (NDA) | March 7, 2024 |
| Naloxone Hydrochloride | 54288-124 | Injection, solution | Generic drugs (ANDA) | November 15, 2023 |
| Phenobarbital Oral Solution | 54288-163 | Solution | Other unapproved drugs | October 27, 2023 |
| Carboplatin | 54288-167 | Injection, solution | Generic drugs (ANDA) | July 31, 2023 |
| Carboplatin | 54288-166 | Injection, solution | Generic drugs (ANDA) | July 31, 2023 |
| Carboplatin | 54288-165 | Injection, solution | Generic drugs (ANDA) | July 31, 2023 |
| Carboplatin | 54288-164 | Injection, solution | Generic drugs (ANDA) | July 31, 2023 |
| Potassium Chloride | 54288-161 | Solution | Generic drugs (ANDA) | July 4, 2023 |
| Potassium Chloride | 54288-160 | Solution | Generic drugs (ANDA) | July 4, 2023 |
| Epinephrine | 54288-117 | Injection | New drug applications (NDA) | May 24, 2023 |
| Methylene Blue | 54288-159 | Injection | Other unapproved drugs | May 15, 2023 |
| Mycophenolate Mofetil | 54288-141 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | March 8, 2023 |
| Epinephrine | 54288-600 | Injection | New drug applications (NDA) | January 16, 2023 |
| Aminocaproic acid | 54288-151 | Solution | Generic drugs (ANDA) | May 16, 2022 |
| Epinephrine | 54288-120 | Injection | New drug applications (NDA) | March 16, 2022 |
| Phenobarbital Sodium | 54288-137 | Injection | Other unapproved drugs | January 7, 2022 |
| Phenobarbital Sodium | 54288-136 | Injection | Other unapproved drugs | January 7, 2022 |
| Methylene Blue | 54288-147 | Injection | Other unapproved drugs | December 23, 2021 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.